ID   SIAT1_RAT               Reviewed;         403 AA.
AC   P13721; D4ABR2; G3V680;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   02-DEC-2020, sequence version 2.
DT   24-JUL-2024, entry version 171.
DE   RecName: Full=Beta-galactoside alpha-2,6-sialyltransferase 1;
DE            Short=Alpha 2,6-ST 1;
DE            EC=2.4.3.1 {ECO:0000269|PubMed:11278697, ECO:0000269|PubMed:24155237, ECO:0000269|PubMed:3121604};
DE   AltName: Full=CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1;
DE   AltName: Full=ST6Gal I;
DE            Short=ST6GalI;
DE   AltName: Full=Sialyltransferase 1;
GN   Name=St6gal1; Synonyms=Siat1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM RLA), PROTEIN SEQUENCE OF 64-79 AND
RP   329-357, FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBCELLULAR LOCATION,
RP   GLYCOSYLATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=3121604; DOI=10.1016/s0021-9258(18)45441-5;
RA   Weinstein J., Lee E.U., McEntee K., Lai P.-H., Paulson J.C.;
RT   "Primary structure of beta-galactoside alpha 2,6-sialyltransferase.
RT   Conversion of membrane-bound enzyme to soluble forms by cleavage of the
RT   NH2-terminal signal anchor.";
RL   J. Biol. Chem. 262:17735-17743(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM RKA), IDENTIFICATION (ISOFORMS RLA AND
RP   RKB), AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=1733948; DOI=10.1016/s0021-9258(18)45909-1;
RA   Wen D.X., Svensson E.C., Paulson J.C.;
RT   "Tissue-specific alternative splicing of the beta-galactoside alpha 2,6-
RT   sialyltransferase gene.";
RL   J. Biol. Chem. 267:2512-2518(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-240 (ISOFORM RKA), IDENTIFICATION (ISOFORMS
RP   RLA AND RKB), AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Kidney, and Liver;
RX   PubMed=1983783; DOI=10.1093/glycob/1.1.25;
RA   Wang X., O'Hanlon T.P., Young R.F., Lau J.T.Y.;
RT   "Rat beta-galactoside alpha 2,6-sialyltransferase genomic organization:
RT   alternate promoters direct the synthesis of liver and kidney transcripts.";
RL   Glycobiology 1:25-31(1990).
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND MONOMER.
RC   STRAIN=Sprague-Dawley; TISSUE=Kidney;
RX   PubMed=2793863; DOI=10.1016/s0021-9258(18)71506-8;
RA   O'Hanlon T.P., Lau K.M., Wang X., Lau J.T.Y.;
RT   "Tissue-specific expression of beta-galactoside alpha-2,6-
RT   sialyltransferase. Transcript heterogeneity predicts a divergent
RT   polypeptide.";
RL   J. Biol. Chem. 264:17389-17394(1989).
RN   [7]
RP   DISULFIDE BOND, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF ARG-180; CYS-181; CYS-332 AND ASP-333.
RX   PubMed=11278697; DOI=10.1074/jbc.m010542200;
RA   Datta A.K., Chammas R., Paulson J.C.;
RT   "Conserved cysteines in the sialyltransferase sialylmotifs form an
RT   essential disulfide bond.";
RL   J. Biol. Chem. 276:15200-15207(2001).
RN   [8] {ECO:0007744|PDB:4MPS}
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 95-403, GLYCOSYLATION AT ASN-146
RP   AND ASN-158, DISULFIDE BONDS, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF TYR-119; PHE-208; ASN-230; SER-231; GLN-232;
RP   ASP-271; TYR-272; SER-319; CYS-350; GLN-354; LYS-355; CYS-361; TYR-366 AND
RP   HIS-367.
RX   PubMed=24155237; DOI=10.1074/jbc.m113.519041;
RA   Meng L., Forouhar F., Thieker D., Gao Z., Ramiah A., Moniz H., Xiang Y.,
RA   Seetharaman J., Milaninia S., Su M., Bridger R., Veillon L., Azadi P.,
RA   Kornhaber G., Wells L., Montelione G.T., Woods R.J., Tong L., Moremen K.W.;
RT   "Enzymatic basis for N-glycan sialylation: structure of rat alpha2,6-
RT   sialyltransferase (ST6GAL1) reveals conserved and unique features for
RT   glycan sialylation.";
RL   J. Biol. Chem. 288:34680-34698(2013).
CC   -!- FUNCTION: Transfers sialic acid from CMP-sialic acid to galactose-
CC       containing acceptor substrates. {ECO:0000269|PubMed:11278697,
CC       ECO:0000269|PubMed:24155237, ECO:0000269|PubMed:3121604}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a beta-D-galactoside + CMP-N-acetyl-beta-neuraminate = an N-
CC         acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl derivative + CMP +
CC         H(+); Xref=Rhea:RHEA:52104, ChEBI:CHEBI:15378, ChEBI:CHEBI:28034,
CC         ChEBI:CHEBI:57812, ChEBI:CHEBI:60377, ChEBI:CHEBI:136398; EC=2.4.3.1;
CC         Evidence={ECO:0000269|PubMed:11278697, ECO:0000269|PubMed:24155237,
CC         ECO:0000269|PubMed:3121604};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=92 uM for donor CMP-Neu5Ac (at pH 6.5 and 37 degrees Celsius);
CC         KM=1.8 mM for acceptor beta-Gal1,4-GlcNAc (at pH 6.5 and 37 degrees
CC         Celsius);
CC         Note=kcat is 35.6 min(-1) for the donor CMP-Neu5Ac (at pH 6.5 and 37
CC         degrees Celsius). kcat is 40.3 min(-1) for the acceptor beta-Gal1,4-
CC         GlcNAc (at pH 6.5 and 37 degrees Celsius).;
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC       {ECO:0000269|PubMed:3121604}.
CC   -!- SUBUNIT: Homodimer (By similarity). Monomer in its soluble form
CC       (PubMed:11278697). {ECO:0000250|UniProtKB:P15907,
CC       ECO:0000269|PubMed:11278697}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, Golgi stack membrane
CC       {ECO:0000269|PubMed:3121604}; Single-pass type II membrane protein
CC       {ECO:0000305}. Secreted {ECO:0000269|PubMed:11278697,
CC       ECO:0000269|PubMed:3121604}. Note=Membrane-bound form in trans
CC       cisternae of Golgi. Secreted into the body fluid.
CC       {ECO:0000269|PubMed:11278697, ECO:0000269|PubMed:3121604}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=3;
CC       Name=RLA {ECO:0000303|PubMed:1983783};
CC         IsoId=P13721-1; Sequence=Displayed;
CC       Name=RKA {ECO:0000303|PubMed:1983783};
CC         IsoId=P13721-2; Sequence=VSP_001782;
CC       Name=RKB {ECO:0000303|PubMed:1983783};
CC         IsoId=P13721-3; Sequence=VSP_001783;
CC   -!- TISSUE SPECIFICITY: Expressed in hepatocytes (at protein level)
CC       (PubMed:11278697, PubMed:3121604). Strongly expressed in liver, spleen,
CC       lung, kidney and submaxillary gland and weakly in heart and brain
CC       (PubMed:1733948, PubMed:2793863). {ECO:0000269|PubMed:11278697,
CC       ECO:0000269|PubMed:1733948, ECO:0000269|PubMed:2793863,
CC       ECO:0000269|PubMed:3121604}.
CC   -!- TISSUE SPECIFICITY: [Isoform RLA]: Expressed in liver.
CC       {ECO:0000269|PubMed:1983783}.
CC   -!- TISSUE SPECIFICITY: [Isoform RKA]: Expressed in kidney, but not in
CC       liver. {ECO:0000269|PubMed:1733948, ECO:0000269|PubMed:1983783}.
CC   -!- TISSUE SPECIFICITY: [Isoform RKB]: Expressed in kidney, but not in
CC       liver. {ECO:0000269|PubMed:1733948, ECO:0000269|PubMed:1983783}.
CC   -!- PTM: The soluble form derives from the membrane form by proteolytic
CC       processing. {ECO:0000269|PubMed:3121604}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:3121604}.
CC   -!- MISCELLANEOUS: [Isoform RKA]: Produced by alternative promoter usage.
CC       The alternative promoter is active in kidney.
CC       {ECO:0000269|PubMed:1983783}.
CC   -!- MISCELLANEOUS: [Isoform RKB]: Produced by alternative splicing of
CC       isoform RKA. {ECO:0000269|PubMed:1983783}.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 29 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M18769; AAA41196.1; -; mRNA.
DR   EMBL; M73987; AAB06269.1; -; mRNA.
DR   EMBL; M83143; AAB07233.1; -; mRNA.
DR   EMBL; AABR07034602; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07034601; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR07034600; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH473999; EDL78084.1; -; Genomic_DNA.
DR   EMBL; CH473999; EDL78085.1; -; Genomic_DNA.
DR   PIR; A28451; A28451.
DR   PIR; C42327; C42327.
DR   RefSeq; NP_001106815.1; NM_001113344.1. [P13721-1]
DR   RefSeq; NP_671738.2; NM_147205.2.
DR   RefSeq; XP_006248563.1; XM_006248501.1. [P13721-1]
DR   RefSeq; XP_008767014.1; XM_008768792.2.
DR   PDB; 4MPS; X-ray; 2.40 A; A/B=95-403.
DR   PDBsum; 4MPS; -.
DR   AlphaFoldDB; P13721; -.
DR   SMR; P13721; -.
DR   IntAct; P13721; 1.
DR   STRING; 10116.ENSRNOP00000002496; -.
DR   BindingDB; P13721; -.
DR   ChEMBL; CHEMBL4276; -.
DR   CAZy; GT29; Glycosyltransferase Family 29.
DR   GlyCosmos; P13721; 2 sites, No reported glycans.
DR   GlyGen; P13721; 2 sites.
DR   iPTMnet; P13721; -.
DR   PhosphoSitePlus; P13721; -.
DR   PaxDb; 10116-ENSRNOP00000002499; -.
DR   Ensembl; ENSRNOT00000002496.8; ENSRNOP00000002496.6; ENSRNOG00000001823.9. [P13721-1]
DR   GeneID; 25197; -.
DR   KEGG; rno:25197; -.
DR   UCSC; RGD:3676; rat. [P13721-1]
DR   AGR; RGD:3676; -.
DR   CTD; 6480; -.
DR   RGD; 3676; St6gal1.
DR   eggNOG; KOG2692; Eukaryota.
DR   GeneTree; ENSGT00940000157053; -.
DR   HOGENOM; CLU_038334_0_0_1; -.
DR   InParanoid; P13721; -.
DR   OMA; HCHLRDH; -.
DR   OrthoDB; 5348004at2759; -.
DR   PhylomeDB; P13721; -.
DR   TreeFam; TF323961; -.
DR   BRENDA; 2.4.99.1; 5301.
DR   Reactome; R-RNO-4085001; Sialic acid metabolism.
DR   Reactome; R-RNO-975577; N-Glycan antennae elongation.
DR   Reactome; R-RNO-977068; Termination of O-glycan biosynthesis.
DR   SABIO-RK; P13721; -.
DR   UniPathway; UPA00378; -.
DR   EvolutionaryTrace; P13721; -.
DR   PRO; PR:P13721; -.
DR   Proteomes; UP000002494; Chromosome 11.
DR   Proteomes; UP000234681; Chromosome 11.
DR   Bgee; ENSRNOG00000001823; Expressed in liver and 20 other cell types or tissues.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IBA:GO_Central.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005797; C:Golgi medial cisterna; IDA:RGD.
DR   GO; GO:0000139; C:Golgi membrane; ISO:RGD.
DR   GO; GO:0000138; C:Golgi trans cisterna; IDA:RGD.
DR   GO; GO:0003835; F:beta-galactoside alpha-2,6-sialyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0008373; F:sialyltransferase activity; IDA:RGD.
DR   GO; GO:0006054; P:N-acetylneuraminate metabolic process; ISS:UniProtKB.
DR   GO; GO:0050922; P:negative regulation of chemotaxis; IDA:RGD.
DR   GO; GO:2000110; P:negative regulation of macrophage apoptotic process; IDA:RGD.
DR   GO; GO:0032946; P:positive regulation of mononuclear cell proliferation; IDA:RGD.
DR   GO; GO:0006486; P:protein glycosylation; ISO:RGD.
DR   GO; GO:0018279; P:protein N-linked glycosylation via asparagine; ISS:UniProtKB.
DR   GO; GO:1900024; P:regulation of substrate adhesion-dependent cell spreading; IDA:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0097503; P:sialylation; ISS:UniProtKB.
DR   Gene3D; 3.90.1480.20; Glycosyl transferase family 29; 1.
DR   InterPro; IPR001675; Glyco_trans_29.
DR   InterPro; IPR038578; GT29-like_sf.
DR   InterPro; IPR012163; Sialyl_trans.
DR   PANTHER; PTHR46059; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; 1.
DR   PANTHER; PTHR46059:SF2; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE 1; 1.
DR   Pfam; PF00777; Glyco_transf_29; 1.
DR   PIRSF; PIRSF005557; Sialyl_trans; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Glycosyltransferase; Golgi apparatus; Membrane; Phosphoprotein;
KW   Reference proteome; Secreted; Signal-anchor; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..403
FT                   /note="Beta-galactoside alpha-2,6-sialyltransferase 1"
FT                   /id="PRO_0000149251"
FT   TOPO_DOM        1..9
FT                   /note="Cytoplasmic"
FT   TRANSMEM        10..26
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        27..403
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   REGION          63..403
FT                   /note="Catalytic (soluble form)"
FT                   /evidence="ECO:0000305|PubMed:3121604"
FT   BINDING         186
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   BINDING         209
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   BINDING         230
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   BINDING         319..321
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   BINDING         350
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   BINDING         351
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   BINDING         362
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   BINDING         366
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         373
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   MOD_RES         366
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   CARBOHYD        146
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24155237,
FT                   ECO:0007744|PDB:4MPS"
FT   CARBOHYD        158
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24155237,
FT                   ECO:0007744|PDB:4MPS"
FT   DISULFID        139..403
FT                   /evidence="ECO:0000269|PubMed:24155237,
FT                   ECO:0007744|PDB:4MPS"
FT   DISULFID        181..332
FT                   /evidence="ECO:0000269|PubMed:11278697,
FT                   ECO:0000269|PubMed:24155237, ECO:0007744|PDB:4MPS"
FT   DISULFID        350..361
FT                   /evidence="ECO:0000250|UniProtKB:P15907"
FT   VAR_SEQ         1..232
FT                   /note="MIHTNLKKKFSLFILVFLLFAVICVWKKGSDYEALTLQAKEFQMPKSQEKVA
FT                   MGSASQVVFSNSKQDPKEDIPILSYHRVTAKVKPQPSFQVWDKDSTYSKLNPRLLKIWR
FT                   NYLNMNKYKVSYKGPGPGVKFSVEALRCHLRDHVNVSMIEATDFPFNTTEWEGYLPKEN
FT                   FRTKVGPWQRCAVVSSAGSLKNSQLGREIDNHDAVLRFNGAPTDNFQQDVGSKTTIRLM
FT                   NSQ -> MRYLLFWYGLPHSYSQCVCHWTPASGIFENEPLLSLLLLVLGK (in
FT                   isoform RKA)"
FT                   /evidence="ECO:0000269|PubMed:1983783"
FT                   /id="VSP_001782"
FT   VAR_SEQ         1..232
FT                   /note="MIHTNLKKKFSLFILVFLLFAVICVWKKGSDYEALTLQAKEFQMPKSQEKVA
FT                   MGSASQVVFSNSKQDPKEDIPILSYHRVTAKVKPQPSFQVWDKDSTYSKLNPRLLKIWR
FT                   NYLNMNKYKVSYKGPGPGVKFSVEALRCHLRDHVNVSMIEATDFPFNTTEWEGYLPKEN
FT                   FRTKVGPWQRCAVVSSAGSLKNSQLGREIDNHDAVLRFNGAPTDNFQQDVGSKTTIRLM
FT                   NSQ -> MRYLLFWYGLPHS (in isoform RKB)"
FT                   /evidence="ECO:0000269|PubMed:1983783"
FT                   /id="VSP_001783"
FT   MUTAGEN         119
FT                   /note="Y->A: Protein destabilization."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         119
FT                   /note="Y->F: No effect on protein stability, nor on
FT                   catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         180
FT                   /note="R->A: Small decrease of sialyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:11278697"
FT   MUTAGEN         181
FT                   /note="C->A: Loss of sialyltransferase activity and
FT                   aberrant subcellular location."
FT                   /evidence="ECO:0000269|PubMed:11278697"
FT   MUTAGEN         208
FT                   /note="F->A: Reduced KM/kcat values for CMP-Neu5Ac, no
FT                   effect on kinetic constants for beta-Gal1,4-GlcNAc."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         230
FT                   /note="N->A: Loss of catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         231
FT                   /note="S->A: Protein destabilization."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         232
FT                   /note="Q->A: Decreased catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         271
FT                   /note="D->A: Decreased catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         272
FT                   /note="Y->A: Strongly decreased catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         319
FT                   /note="S->A: Protein destabilization."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         332
FT                   /note="C->A: Loss of sialyltransferase activity and
FT                   aberrant subcellular location."
FT                   /evidence="ECO:0000269|PubMed:11278697"
FT   MUTAGEN         332
FT                   /note="C->S: Loss of sialyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:11278697"
FT   MUTAGEN         333
FT                   /note="D->A: Small decrease of sialyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:11278697"
FT   MUTAGEN         350
FT                   /note="C->A: Loss of catalytic activity; when associated
FT                   with A-361."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         354
FT                   /note="Q->A: No effect on catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         355
FT                   /note="K->A: No effect on catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         361
FT                   /note="C->A: Loss of catalytic activity; when associated
FT                   with A-350."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         366
FT                   /note="Y->A: Loss of catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   MUTAGEN         367
FT                   /note="H->A: Loss of catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:24155237"
FT   CONFLICT        367
FT                   /note="H -> D (in Ref. 1; AAA41196)"
FT   HELIX           107..115
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           134..144
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   TURN            155..158
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   TURN            160..165
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   TURN            172..174
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          178..184
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           188..190
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           196..200
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          201..208
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   TURN            214..216
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           217..220
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          225..230
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           231..236
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           238..241
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           244..247
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          248..254
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           263..268
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           275..284
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          290..293
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           297..308
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          309..311
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           320..329
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          332..341
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          348..352
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          365..367
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           369..379
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   HELIX           384..389
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   STRAND          392..396
FT                   /evidence="ECO:0007829|PDB:4MPS"
FT   CONFLICT        P13721-2:40
FT                   /note="V -> L (in Ref. 5; AAB06269)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   403 AA;  46754 MW;  F40D7EA6B59355DA CRC64;
     MIHTNLKKKF SLFILVFLLF AVICVWKKGS DYEALTLQAK EFQMPKSQEK VAMGSASQVV
     FSNSKQDPKE DIPILSYHRV TAKVKPQPSF QVWDKDSTYS KLNPRLLKIW RNYLNMNKYK
     VSYKGPGPGV KFSVEALRCH LRDHVNVSMI EATDFPFNTT EWEGYLPKEN FRTKVGPWQR
     CAVVSSAGSL KNSQLGREID NHDAVLRFNG APTDNFQQDV GSKTTIRLMN SQLVTTEKRF
     LKDSLYTEGI LIVWDPSVYH ADIPKWYQKP DYNFFETYKS YRRLNPSQPF YILKPQMPWE
     LWDIIQEISA DLIQPNPPSS GMLGIIIMMT LCDQVDIYEF LPSKRKTDVC YYHQKFFDSA
     CTMGAYHPLL FEKNMVKHLN EGTDEDIYLF GKATLSGFRN IRC
//
